4TEEN4 Pharmaceuticals Secures €55 Million to Advance Procizumab in Cardiogenic Shock
核心洞察
4TEEN4 Pharmaceuticals (搜索) has extended its Series C financing round to €55 million to support the ongoing Phase 2a clinical trial of procizumab, a first-in-class monoclonal antibody targeting cardiogenic shock (搜索).
Procizumab is designed to neutralize circulating dipeptidyl peptidase 3 (搜索) (cDPP3 (搜索)), a cardiac depression factor that drives shock pathology and is associated with mortality rates exceeding 50%.
The funding will expand the PROCARD 2a study across Europe and support planned U.S. expansion, with interim safety and pharmacokinetic data expected in early 2026.
4TEEN4 Pharmaceuticals (搜索) GmbH announced the extension of its Series C financing round to €55 million ($64 million), securing participation from both existing and new investors to advance the clinical development of procizumab, a first-in-class monoclonal antibody therapy for cardiogenic shock (搜索). The company dosed its first patient in the ongoing Phase 2a trial in July 2025 and expects initial interim results in early 2026.
Addressing Critical Unmet Medical Need
Cardiogenic shock (搜索) represents the second most common form of circulatory failure, most often triggered by acute myocardial infarction (搜索) or acute decompensated heart failure (搜索). Despite advances in supportive care, the condition remains a major unmet medical need with no approved therapies targeting its underlying causes and mortality rates exceeding 50%. Shock accounts for approximately one in three admissions to intensive care units and is characterized by acute circulatory failure that often leads to multi-organ failure (搜索).
Novel Mechanism of Action
Procizumab is designed to selectively target circulating dipeptidyl peptidase 3 (搜索) (cDPP3 (搜索)), a cardiac depression factor and key pathological driver in shock. Under normal physiological conditions, DPP3 functions as an intracellular enzyme. However, when released into circulation following cellular injury, it degrades angiotensin peptides, resulting in dysregulation of the renin-angiotensin-aldosterone system (搜索) (RAAS). This loss of RAAS control can lead to shock, broad organ failure, and ultimately death.
By inhibiting cDPP3 (搜索) activity, procizumab restores RAAS balance and stabilizes cardiovascular function. The therapeutic potential has been demonstrated in preclinical and clinical settings, where it effectively normalized cardiovascular parameters, reversed organ dysfunction, and increased survival while exhibiting a favorable safety and tolerability profile in a completed Phase 1 study in healthy volunteers.
Clinical Development Progress
The ongoing multicenter, randomized, double-blind, placebo-controlled Phase 2a PROCARD 2a trial is evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of procizumab in patients with cardiogenic shock (搜索) and elevated cDPP3 (搜索) levels. The additional funding will support continued enrollment and expand the study footprint across Europe while preparing for planned expansion into the United States.
"This financing reflects a strong vote of confidence in 4TEEN4's mission and the transformative potential of our science to improve survival in critically ill patients," said Dr. Andreas Bergmann, CEO of 4TEEN4 Pharmaceuticals (搜索). "This investment enables us to advance our PROCARD 2a study, creating a comprehensive framework for our planned pivotal study for procizumab."
Strategic Financial Position
Dr. Kilian von Seldeneck, CFO of 4TEEN4 Pharmaceuticals (搜索), emphasized the strategic importance of the funding: "The proceeds from our Series C strengthen our financial position and will be used to reach key clinical milestones for procizumab, including the interim safety, pharmacokinetic, and pharmacodynamic analysis expected in early 2026, as well as subsequent PROCARD 2a readouts."
The Series C extension was supported by prior institutional investors, new institutional funds, family offices, and private investors. The capital will enable the company to further de-risk its lead candidate and accelerate progress toward data that could transform care for patients in urgent need of treatment options.
Moving Beyond Supportive Care
4TEEN4's approach represents a potential paradigm shift in shock treatment by targeting the root biological cause rather than providing only supportive measures. The company's mission focuses on reversing life-threatening shock and restoring organ function through this highly specific therapeutic intervention, aiming to improve survival outcomes in critically ill patients who currently have limited treatment options.